HER2 positive endometrial cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:03:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png HER2 positive endometrial cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer https://clinicaltrials.eu/trial/study-of-zanidatamab-in-adults-with-her2-positive-solid-tumors-including-endometrial-colorectal-head-and-neck-cancers-sarcoma-or-her2-mutant-non-small-cell-lung-cancer/ Thu, 30 Apr 2026 13:07:57 +0000 https://clinicaltrials.eu/trial/study-of-zanidatamab-in-adults-with-her2-positive-solid-tumors-including-endometrial-colorectal-head-and-neck-cancers-sarcoma-or-her2-mutant-non-small-cell-lung-cancer/ This clinical trial focuses on treating patients with various types of solid tumors that have specific characteristics related to the HER2 gene. The study includes several types of cancer: endometrial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, and sarcoma. These cancers must either show high levels of HER2 protein or have mutations in the HER2 gene.

The study uses a medication called zanidatamab (also known as JZP598), which is given through an intravenous infusion. This medicine is a powder that is first made into a concentrated solution before being given to patients. The maximum daily dose that can be given is 2400 milligrams, and treatment may continue for up to three years.

The main goal of this research is to determine how well zanidatamab works in treating these different types of cancer. The study will look at whether tumors respond to the treatment by shrinking or disappearing. Doctors will monitor patients regularly using scans to check how the tumors are responding to the treatment and to watch for any side effects that may occur.

]]> Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-versus-chemotherapy-as-additional-treatment-after-surgery-for-patients-with-her2-positive-endometrial-cancer/ Wed, 29 Apr 2026 15:08:44 +0000 https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-versus-chemotherapy-as-additional-treatment-after-surgery-for-patients-with-her2-positive-endometrial-cancer/ This study is looking at endometrial cancer that expresses a protein called HER2. Endometrial cancer is a type of cancer that starts in the lining of the uterus. The study will test a medication called DS-8201a, which is also known as trastuzumab deruxtecan. This medication will be compared to standard chemotherapy treatments that may include carboplatin, paclitaxel, cisplatin, or docetaxel. Some participants may also receive radiotherapy, which is a treatment using radiation to destroy cancer cells. The study will involve people who have had surgery to remove their cancer and currently have no signs of disease remaining.

The purpose of the study is to compare how well DS-8201a works compared to standard chemotherapy in preventing the cancer from coming back. The study will look at how long participants remain free of disease after treatment. Participants will be randomly assigned to receive either DS-8201a or one of the standard chemotherapy combinations. All medications will be given through a vein as an infusion. The treatment period can last up to 51 cycles for DS-8201a or between 4 to 18 cycles for the standard chemotherapy options, depending on which treatment is assigned. A cycle is a repeating period of time during which the medication is given.

During the study, participants will have regular check-ups that include imaging scans to look for any signs of cancer returning, blood tests to check organ function and blood cell counts, heart function tests using ultrasound or similar scans, and eye examinations. The study will also measure how participants feel and their quality of life using questionnaires. The doctors will monitor for any side effects or unwanted reactions to the medications throughout the study. The study will also collect blood samples to measure the levels of the study medication in the body and to check if the body develops any immune response to the treatment.

]]>